Citadel Advisors’s Lipocine LPCN Stock Holding History

Citadel Advisors’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-53	Closed	-$286	–	14859
2023 Q1	$286	Sell	53 -665	-93%	-$5.14K	﹤0.01%	14527
2022 Q4	$4.68K	Sell	718 -6	-0.8%	-$44	﹤0.01%	14077
2022 Q3	$6K	Buy	724 +12	+2%	+$134	﹤0.01%	12347
2022 Q2	$10K	Sell	712 -1,759	-71%	-$27.4K	﹤0.01%	12578
2022 Q1	$58K	Buy	2,471 +1,036	+72%	+$21.7K	﹤0.01%	12698
2021 Q4	$24K	Sell	1,435 -1,700	-54%	-$31.6K	﹤0.01%	13542
2021 Q3	$58K	Sell	3,135 -118	-4%	-$2.6K	﹤0.01%	13286
2021 Q2	$77K	Sell	3,253 -2,076	-39%	-$48.8K	﹤0.01%	13101
2021 Q1	$137K	Buy	+5,329	New	+$154K	﹤0.01%	12151
2019 Q4	–	Sell	-682	Closed	-$33K	–	9467
2019 Q3	$33K	Buy	+682	New	+$27.4K	﹤0.01%	8823

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $606M AUM

Citadel Advisors's LPCN Position: Q2 2026 in Review

Citadel Advisors increased its Lipocine (LPCN) stake by 179% in Q2 2026, buying an estimated $125K and bringing the position to 81,221 shares worth $208K. The position accounts for ﹤0.01% of the portfolio, ranked #11984.

Citadel Advisors first reported a position in LPCN in Q3 2015 and has held it in 17 quarters since. The position peaked at $820K in Q3 2015. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

Citadel Advisors held 81,221 shares of Lipocine worth $208K as of Q2 2026.
Citadel Advisors bought 52,133 Lipocine shares in Q2 2026, an estimated $125K.
Lipocine made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #11984 holding.
Citadel Advisors first reported a position in Lipocine in Q3 2015 and has held it in 17 quarters since.
Citadel Advisors's Lipocine position peaked at $820K in Q3 2015.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.